Daptomycin in paediatrics: current knowledge and the need for future research
Open Access
- 17 November 2014
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 70 (3) , 643-648
Abstract
To overcome the problems stemming from antimicrobial resistance, there have been several attempts to develop new antimicrobials in recent years. Of the highly potent drugs targeting resistant Gram-positive bacteria, daptomycin has a number of attractive characteristics that suggest its possible use in the treatment of serious infections due to these organisms. Although several pharmacokinetic and clinical studies in adults have provided data to determine how this drug should be prescribed to obtain the maximal clinical efficacy without significant risks of severe adverse events, we have not yet solved all of the problems related to the use of this antibiotic in paediatric patients. In this paper, the resolved and lingering problems of daptomycin treatment in newborns and children are reviewed and discussed. Studies have indicated that daptomycin is a promising therapeutic option for the treatment of paediatric diseases caused by MDR Gram-positive bacilli. However, before daptomycin can be licensed for use in newborns and children, further studies are needed to establish the appropriate dosages for paediatric patients of different ages. The data collected in adults can only be transferred to children older than 12 years, and the information available is not sufficient to determine the dosage that will assure the highest antimicrobial efficacy with only marginal risks of adverse events in younger patients. Thus, studies in neonates and younger infants are urgently needed to permit the use of daptomycin in the first months of life, a period in which infections due to MDR Gram-positive pathogens are increasing.Keywords
This publication has 53 references indexed in Scilit:
- Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: Summary of 8 years of a Worldwide Surveillance Programme (2005–2012)International Journal of Antimicrobial Agents, 2014
- Epidemiology and clinical relevance of microbial resistance determinants versus anti-Gram-positive agentsCurrent Opinion in Microbiology, 2010
- Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused byStaphylococcus aureusNew England Journal of Medicine, 2006
- Daptomycin in vitro susceptibility in European Gram-positive clinical isolatesInternational Journal of Antimicrobial Agents, 2004
- Daptomycin: Another Novel Agent for Treating Infections Due to Drug‐Resistant Gram‐Positive PathogensClinical Infectious Diseases, 2004
- In Vitro Activity of Daptomycin against Gram-Positive European Clinical Isolates with Defined Resistance DeterminantsAntimicrobial Agents and Chemotherapy, 2004
- Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organismsJournal of Antimicrobial Chemotherapy, 2004
- The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus speciesJournal of Antimicrobial Chemotherapy, 2003
- Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001Journal of Antimicrobial Chemotherapy, 2003
- In Vitro and In Vivo Activities of Tigecycline (GAR-936), Daptomycin, and Comparative Antimicrobial Agents against Glycopeptide-IntermediateStaphylococcus aureusand Other Resistant Gram-Positive PathogensAntimicrobial Agents and Chemotherapy, 2002